Two drug companies will pay a combined $49.1 million for their alleged involvement in schemes to inflate drug prices and limit competition in the generic pharmaceuticals market nationwide, the Connecticut Law Tribune reported Oct. 31.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
